Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

Precision T1D Platform - New Therapies for Cardio-Renal Complications

2026. augusztus 5. frissítette: Rodica Busui, Oregon Health and Science University

Accelerating Breakthrough Targeted New Therapies for Cardio-Renal Complications in People With T1D (Precision T1D Platform)

Breakthrough T1D has awarded support for a joint University of Michigan-Oregon Health & Science University Center of Excellence (CoE) to address cardio-renal complications in T1D. The overarching hypothesis of the CoE is that individuals with T1D have unique endophenotypes determining their progression towards cardio-renal end organ damage. Defining the underlying molecular programs in T1D endophenotypes provides the rationale for testing existing or new drug candidates in mechanistic trials targeting T1D cardio-renal complications by matching endophenotypes to targeted therapies.

A tanulmány áttekintése

Részletes leírás

This is a multicenter, open label pilot platform study to evaluate the impact of allocating patients with T1D and early signs of HF/DKD to targeted therapies based on their disease pathway activation signatures. The hypothesis is that stratifying T1D patients by molecularly-defined endophenotypes enables the use of targeted therapies that can more effectively prevent or slow cardio-renal complications.

There is no randomized allocation to treatment arms; rather, the eligible participant's clinical and biomarker data will be reviewed by the Molecular T1D Board which will adjudicate each participant to a treatment arm based on their based on their disease pathway activation signatures. Activation of different treatment arms may be initiated at different time points during the study.

The following sections describe the master protocol, outlining the requirements across all treatment arms, including the study-wide inclusion and exclusion criteria and study-wide procedures. Appendix A outlines any treatment arm/investigational agent specific information, including defining additional treatment-specific eligibility criteria and required study procedures.

The study schema can be found in Section 1.2 and the Schedule of Activities (SoA) in Section 1.3. Potential participants will undergo a two-part consent and screening process. The initial consent and screening visit will be limited to activities necessary for assessment by the Molecular T1D Board. Following review by the Molecular T1D Board, participants will be adjudicated to one treatment arm. At this time, participants will undergo the second consent and screening step, which will include information about specific requirements for their assigned investigational arm and, if in agreement, a complete eligibility assessment via a full screening visit. If the participant is deemed eligible, they will be notified and investigational product will be mailed to them directly. The screening visit results will also serve as the baseline results provided the first dose of study drug is taken within 14 (target) to 21 (limit) days of the screening visit. If more than 21 days, a retest of all laboratory measures will be performed.

Participants will receive open label treatment for 26 weeks, with planned study visits at weeks 2, 6, 12, 26, and 30. The total study duration of participation will be up to 36 weeks, inclusive of the screening period. Active study participation will conclude at Week 30 visit. Following completion of active study participation, participants will enter a passive follow-up period during which the study team may collect information on vital status, survival, hospitalizations, and other relevant clinical outcomes through review of medical records and other authorized data sources for up to 12 months after study participation ended. No additional protocol-required visits, procedures, or interventions will be conducted during the passive follow-up period. Participants will be enrolled in this study at Oregon Health & Science University and the University of Michigan.

The currently planned number of study arms is three, with 15-19 participants enrolled in each arm. The study sponsors will have the option to increase the number of study arms and potential targeted therapies, which would be documented in the appendices and this master protocol.

Tanulmány típusa

Beavatkozó

Beiratkozás (Becsült)

57

Fázis

  • 2. fázis

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi kapcsolat

Tanulmányozza a kapcsolattartók biztonsági mentését

Tanulmányi helyek

    • Michigan
      • Ann Arbor, Michigan, Egyesült Államok, 48109
        • University of Michigan
        • Alkutató:
          • Matthias Kretzler, MD
        • Kapcsolatba lépni:
        • Kutatásvezető:
          • Lynn Ang, MD
    • Oregon
      • Portland, Oregon, Egyesült Államok, 97239
        • Oregon Health & Science University
        • Kutatásvezető:
          • Rodica Busui, MD, PhD
        • Alkutató:
          • Brian Davidson, MD
        • Kapcsolatba lépni:
        • Kapcsolatba lépni:
          • Aly Carlson
          • Telefonszám: 971-610-3005
        • Alkutató:
          • Jonathan Purnell, MD
        • Alkutató:
          • David Ellison, MD
        • Alkutató:
          • Kristin Childress, MD, MPH

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

  • Felnőtt
  • Idősebb felnőtt

Egészséges önkénteseket fogad

Nem

Leírás

Inclusion Criteria:

  1. Diagnosis of T1D, defined as hyperglycemia requiring treatment with insulin within one year from diagnosis or, if the onset was after age 35 years, documentation of the presence of hyperglycemia and one or more of the following:

    1. presence of circulating T1D-associated autoantibodies, or
    2. history of hospitalization for diabetic ketoacidosis, or
    3. documented plasma C-peptide below the limit of detection with standard assay (with concurrent blood glucose >100 mg/dL)
  2. Aged 18-75 years, inclusive
  3. T1D duration >10 years
  4. HbA1c: 7-10%
  5. Meets one of the following, either

    1. UACR > 30 mg/dl with eGFR ≥ 60mL/min/1.73 m2 and receiving standard of care therapy for early DKD Stage 2, including renin angiotensin system blockade (RASB), unless contraindicated or not tolerated, or
    2. Early (Stage B HF) defined as NT-proBNP ≥125 pg/mL
  6. Willing and able to adhere to schedule of activities and protocol requirements, including written informed consent

Exclusion Criteria:

  1. Diagnosis of Type 2 diabetes or monogenic forms of diabetes or diabetes secondary to pancreatic disease
  2. Use of any active platform treatment arms outside study assignment within 2 months prior to screening. See Appendix A for active treatment arms
  3. Current use of GLP-1 receptor agonists or other non-glucose lowering agent
  4. Use of aldosterone inhibitors within 2 months prior to screening
  5. Immunosuppressive medications within 3 months prior to screening
  6. Systolic BP>160 or diastolic BP >95 mmHg at screening
  7. History of ≥3 severe hypoglycemic events requiring third-party assistance for correction within 3 months prior to screening
  8. Evidence of any episode of DKA or non-ketotic hyperosmolar state within 12 months prior to screening
  9. Serum potassium > 5.0 mmol/L at screening
  10. Absolute neutrophil count < 2.0 × 109 per L at screening
  11. Platelet count < 120 × 109 per L at screening
  12. Known active tuberculosis, hepatitis B or C at screening, or history of HIV
  13. Current or past history of decompensated cirrhosis (defined as variceal bleeding, ascites or hepatic encephalopathy), and/or known diagnosis of cirrhosis based on liver biopsy, imaging, or elastography, and/or AST or ALT >2 times upper limit of normal, and/or total bilirubin >1.3 times upper limit of normal at screening
  14. History of severe acquired immune deficiency syndrome or severely immunocompromised status in the opinion of the study site investigator
  15. History of biopsy-proven non-diabetic CKD
  16. History of any other cause of HF (viral, congenital, valvular)
  17. History of heart or renal transplant or currently on chronic dialysis
  18. Cancer treatment, excluding non-melanoma skin cancer treated by excision, carcinoma in situ of the cervix or uterus, ductal breast cancer in situ, resected non-metastatic breast or prostate cancer, within one year prior to screening
  19. Illicit drug abuse within 6 months prior to screening in the opinion of the study site investigator
  20. Current heavy alcohol use (for men, ≥5 drinks on any day or ≥15 drinks per week; for women, ≥4 drinks on any day or ≥8 drinks per week)
  21. Participation in another interventional clinical research study within 30 days prior to screening
  22. Breastfeeding, pregnancy, or unwillingness to be on contraception during the trial
  23. Presence of a clinically significant medical history, physical examination, laboratory finding or other identified study site investigator concern that may interfere with any aspect of study conduct or interpretation of results

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Kezelés
  • Kiosztás: Véletlenszerűsített
  • Beavatkozó modell: Párhuzamos hozzárendelés
  • Maszkolás: Nincs (Open Label)

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Kísérleti: Finerenone
Study participants with biomarker profiles showing a match for finerenone will be adjudicated to this treatment arm. The clinically recommended dose for finerenone based on manufacturer guidelines is 20 mg once daily (oral) if screening eGFR is ≥60 mL/min/1.73 m2.
Each treatment arm will be a different unique drug. There will be no crossing over of participants between arms. Each participant that is adjudicated to their treatment arm will remain on that arm for the duration of the study through study completion.
Más nevek:
  • KERENDIA
Kísérleti: Sotagliflozin
Study participants with biomarker profiles that match with sotagliflozin will be adjudicated to this treatment arm. The clinically recommended dose of sotagliflozin is 200 mg per the manufacturer guidelines. The dose of 200 mg has a lower DKA risk and similar kidney benefits to the higher doses.
Each treatment arm will be a different unique drug. There will be no crossing over of participants between arms. Each participant that is adjudicated to their treatment arm will remain on that arm for the duration of the study through study completion.
Más nevek:
  • INPEFA

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Markers of Renal Health [Safety and Tolerability]
Időkeret: 26 weeks
The primary efficacy endpoints are measures of early (week 26) outcomes on markers of renal health, defined as the percent change from baseline to week 26 in UACR.
26 weeks
Markes of Cardio Health [Safety and Tolerability]
Időkeret: 26 weeks
The primary efficacy endpoints are measures of early (week 26) outcomes on markers of cardio health as defined by the percent change from baseline to week 26 in NT-proBNP.
26 weeks
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Időkeret: 26 weeks
The primary safety endpoints are defined as incidence of serious adverse events, adverse events and clinically significant abnormal laboratory tests.
26 weeks

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Immediate Outcomes of Renal Health (week 6)
Időkeret: 20 weeks
The secondary endpoints are measures of immediate outcomes on markers of renal health as defined by changes from baseline to week 6 in UACR.
20 weeks
Immediate Outcomes of Cardio Health (week 6)
Időkeret: 20 weeks
The secondary endpoints are measures of immediate outcomes on markers of cardio health as defined by changes from baseline to week 6 in NT-proBNP.
20 weeks
Immediate (week 6) and Early (week 26) Outcomes of Nephron Function Failure
Időkeret: 26 weeks
The secondary endpoints are measures of immediate outcomes on markers of renal function failure as defined by changes from baseline to week 6 and from baseline to week 26 in eGFR.
26 weeks

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Nyomozók

  • Tanulmányi szék: Rodica Busui, MD, PhD, Oregon Health and Science University

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Becsült)

2026. november 1.

Elsődleges befejezés (Becsült)

2029. december 31.

A tanulmány befejezése (Becsült)

2031. december 31.

Tanulmányi regisztráció dátumai

Először benyújtva

2026. május 11.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2026. május 11.

Első közzététel (Tényleges)

2026. május 18.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. augusztus 10.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. augusztus 5.

Utolsó ellenőrzés

2026. augusztus 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Terv az egyéni résztvevői adatokhoz (IPD)

Tervezi megosztani az egyéni résztvevői adatokat (IPD)?

IGEN

IPD terv leírása

A limited dataset along with other study related materials (i.e., protocol, consent template, etc.) will be shared with other researchers/investigators at other institutions such as the University of Michigan via a data use agreement initiated by the primary site, Oregon Health & Science University.

IPD megosztási időkeret

The sharing of information will be available as soon as both institutions sign the data use agreement for a limited dataset. However, the sharing of protocols and consent form language are currently being shared as both institutions are collaborating to draft these documents. This collaborating is facilitated by a subaward contract between two institutions.

IPD-megosztási hozzáférési feltételek

Only study personnel working on the study will have access to study related information. All information is kept on secure share drives at each respective institution and access is only possible if the personnel is an employee with institutional specific credentials to securely log in.

Az IPD megosztását támogató információ típusa

  • STUDY_PROTOCOL
  • NEDV
  • ICF
  • ANALYTIC_CODE
  • CSR

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Igen

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

az Egyesült Államokban gyártott és onnan exportált termék

Igen

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel